Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 6/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | RPA1 | P27694 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PPP1CA | P62136 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27668789 | 0.87 | MARS1 (0.53) | MARS1L3MBTL1RPA1PPP1CAKMT2A | |
| SCHEMBL4927931 | 0.86 | MARS1 (0.52) | MARS1RPA1SMN1; SMN2PPP1CAKMT2A | |
| SCHEMBL5521156 | 0.84 | ALDH1A1 (0.52) | MARS1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5524835 | 0.84 | CNR1 (0.50) | MARS1KMT2AMEN1 | |
| SCHEMBL5522350 | 0.84 | MARS1 (0.50) | MARS1L3MBTL1RPA1PPP1CAKMT2A | |
| SCHEMBL27619816 | 0.81 | RPA1 (0.45) | MARS1L3MBTL1RPA1SMN1; SMN2PPP1CA | |
| SCHEMBL27668657 | 0.80 | MDM2 (0.56) | MARS1 | |
| SCHEMBL4932725 | 0.80 | MARS1 (0.64) | MARS1L3MBTL1RPA1SMN1; SMN2PPP1CA | |
| SCHEMBL2916915 | 0.79 | MARS1 (0.49) | MARS1L3MBTL1RPA1SMN1; SMN2PPP1CA | |
| SCHEMBL5978029 | 0.79 | MARS1 (0.46) | MARS1RPA1PPP1CAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| CN-1902191-A | Amidopyrazole derivative | DAIICHI SEIYAKU CO (JP) | 2007-01-24 | — | — | CN | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | PTGER1, PTGS1, PTGER2 | MARS1 2982/4885L3MBTL1 3071/4885RPA1 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.